Acceleron Pharma

Acceleron Pharma is a biopharmaceutical company that specializes in the discovery, development, and commercialization of therapeutics to treat serious and rare diseases. The company's research focuses on harnessing the power of the body's cellular growth mechanisms to develop innovative treatments for diseases that are currently underserved by existing therapies.

History[edit | edit source]

Acceleron Pharma was founded in 2003 by scientists from the Massachusetts Institute of Technology (MIT) and the Harvard Medical School. The company's initial focus was on the development of therapeutics based on the TGF-beta superfamily of proteins, a group of molecules that play a key role in the regulation of cellular growth and differentiation.

Research and Development[edit | edit source]

Acceleron's research and development efforts are primarily focused on the TGF-beta superfamily of proteins. These proteins are involved in a wide range of biological processes, including cell growth, differentiation, and apoptosis. Acceleron has developed a number of drug candidates that target these proteins, with the aim of treating a variety of serious and rare diseases.

One of the company's most advanced drug candidates is Luspatercept, a first-in-class erythroid maturation agent. Luspatercept is currently being evaluated in late-stage clinical trials for the treatment of myelodysplastic syndromes (MDS) and beta-thalassemia, two rare blood disorders.

Partnerships and Collaborations[edit | edit source]

Acceleron has established several strategic partnerships and collaborations to advance its research and development efforts. These include a collaboration with Celgene Corporation, a global biopharmaceutical company, to develop and commercialize Luspatercept. Acceleron and Celgene are also collaborating on the development of several other drug candidates targeting the TGF-beta superfamily of proteins.

Financial Performance[edit | edit source]

As a biopharmaceutical company, Acceleron's financial performance is largely driven by the progress of its research and development efforts, as well as the success of its strategic partnerships and collaborations. The company's revenues primarily consist of collaboration revenues from its partnership with Celgene.

Search WikiMD

Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD

WikiMD's Wellness Encyclopedia

Let Food Be Thy Medicine
Medicine Thy Food - Hippocrates

Translate this page: - East Asian 中文, 日本, 한국어, South Asian हिन्दी, தமிழ், తెలుగు, Urdu, ಕನ್ನಡ, Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, বাংলা
European español, Deutsch, français, Greek, português do Brasil, polski, română, русский, Nederlands, norsk, svenska, suomi, Italian
Middle Eastern & African عربى, Turkish, Persian, Hebrew, Afrikaans, isiZulu, Kiswahili,
Other Bulgarian, Hungarian, Czech, Swedish, മലയാളം, मराठी, ਪੰਜਾਬੀ, ગુજરાતી, Portuguese, Ukrainian

Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.